Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
复制标题
HCV/HIV 合并感染个体对联合治疗的肝组织学反应 (HR)：干扰素诱导 HR 独立于持续病毒学反应 (SVR)。
DOI：
10.1089/aid.2006.22.1091
复制
发表时间：
2006
影响因子：
1.5
通讯作者：
Polis,MichaelA
中科院分区：
文献类型：
--
作者：
Wu,Lynne;Kottilil,Shyam;Lempicki,Richard;Yang,Jun;McLaughlin,Mary;Hu,Zonghui;Koratich,Chad;Reitano,KristinN;Rehm,CatherineA;Masur,Henry;Wood,Brad;Kleiner,DavidE;Polis,MichaelA
Most HIV/HCV-coinfected patients fail to achieve a sustained virologic response (SVR) to peginterferon-ribavirin therapy. We examined the hepatic histologic response (HR), defined as an improvement in hepatic inflammation scores of two points or more, to combination therapy among HIV/HCV-coinfected subjects. An open label prospective trial treated 32 HIV/HCV-coinfected patients with peginterferon alpha-2b and ribavirin for 48 weeks. Liver biopsies, scored by a single pathologist using the Histology Activity Index (HAI, range 0–18) and Ishak fibrosis scores (range 0–6), were performed before and after treatment. Gene expression profiles of PBMCs were performed using Affymetrix U133A gene chips. A total of 87% of SVR subjects and 88% of nonresponders (NR) had an HR, but no significant change in the liver fibrosis scores was observed (p> 0.05). For genotype 1 patients, a baseline fibrosis score ≤2 was related to a higher likelihood of SVR than those with a score >2 (p= 0.012). Combination therapy for HCV among HIV-coinfected subjects resulted in a modest SVR rate. Persons with mild liver disease had a better SVR rate, suggesting early treatment may be beneficial. Combination therapy resulted in an HR for most of the patients, however, further follow-up of these patients will determine the durability of such an HR.
登录
查看更多内容
影响因子：
11.8
作者：
Martinez-Sierra, C;Arizcorreta, A;Girón-González, JA
通讯作者：
Girón-González, JA
慢性病毒性肝炎和艾滋病毒感染共识会议：更新的西班牙建议
影响因子：
2.5
作者：
V. Soriano;J. Miro;J. García;J. Torre;M. Nunez;J. Romero;L. Martín;J. Castilla;J. Iribarren;C. Quereda;M. Santin;J. González;J. Arribas;I. Santos;J. Hernández;E. Ortega;V. Asensi;M. A. D. Pozo;J. Berenguer;C. Tural;B. Clotet;M. Leal;J. Mallolas;J. Sánchez‐Tapias;S. Moreno;J. Gatell;M. J. Téllez;R. Rubio;E. Ledesma;P. Domingo;P. Barreiro;J. Pedreira;M. Romero;J. González;E. Lissen
通讯作者：
E. Lissen
影响因子：
11.8
作者：
Sherman, KE;Rouster, SD;Rajicic, N
通讯作者：
Rajicic, N
转诊接受 HCV 治疗的低水平免疫抑制的 HIV-HCV 患者的纤维化比 HCV 匹配的患者更严重。
影响因子：
3.3
作者：
A. Rullier;P. Trimoulet;D. Neau;P. Bernard;J. Foucher;D. Lacoste;M. Winnock;Rosa Urbaniak;G. Ballardini;C. Balabaud;P. Bioulac;B. le Bail
通讯作者：
B. le Bail
聚乙二醇干扰素α-2b、利巴韦林和金刚烷胺治疗慢性丙型肝炎
影响因子：
3.1
作者：
Z. Younossi;Arthur C. McCullough;D. Barnes;A. Post;J. Ong;R. O’shea;Lisa M. Martin;Diane Bringman;D. Farmer;G. Levinthal;K. Mullen;W. Carey;A. Tavill;Roy Ferguson;T. Gramlich
通讯作者：
T. Gramlich